In the CREST-2 trial, should patients with asymptomatic carotid stenosis be managed initially with intensive medical therapy rather than carotid endarterectomy or stenting?

CREST-2: Intensive Medical Management Should Be First-Line for Most Asymptomatic Carotid Stenosis Patients

For patients with asymptomatic carotid stenosis ≥70%, intensive medical management (IMM) alone is the appropriate initial strategy for the vast majority of patients, with selective consideration of carotid artery stenting (CAS) only in highly selected cases—carotid endarterectomy (CEA) showed no significant benefit over medical therapy alone in CREST-2. 1

The CREST-2 Evidence

CREST-2 fundamentally challenges decades of practice by demonstrating that modern intensive medical therapy achieves remarkably low stroke rates in asymptomatic carotid stenosis. The trial randomized 2,485 patients with ≥70% asymptomatic stenosis to either revascularization plus IMM versus IMM alone in two parallel trials 2, 3.

Key Findings:

CEA Results:

• Primary endpoint (periprocedural stroke/death or ipsilateral ischemic stroke at 4 years): 3.7% (CEA+IMM) vs 5.3% (IMM alone), p=0.24 1
• No statistically significant benefit despite lower late stroke rates, because early procedural risk offset any long-term advantage 3

CAS Results:

• Primary endpoint: 2.8% (CAS+IMM) vs 6.0% (IMM alone), p=0.02 1
• Showed statistical significance, but this finding requires critical interpretation (see below)

IMM Alone Performance:

• Achieved 4-year stroke rates of 5.3-6.0% in control arms 1
• This represents approximately 1.3-1.5% annual stroke risk—dramatically lower than historical medical therapy

Clinical Decision Algorithm

Step 1: Confirm Asymptomatic Status and Stenosis Severity

• Verify ≥70% stenosis by validated duplex ultrasound or ≥60% by angiography 4
• Ensure truly asymptomatic (no ipsilateral TIA or stroke within 6 months) 5
• Use NASCET method for stenosis measurement 4

Step 2: Initiate Intensive Medical Management for ALL Patients

This is non-negotiable and forms the foundation of treatment 4:

Blood Pressure Control:

• Target systolic BP <130 mmHg 6
• CREST-2 achieved mean SBP reduction from 139.7 to 130.3 mmHg 6

Lipid Management:

• Target LDL <70 mg/dL with high-intensity statin 6
• CREST-2 achieved mean LDL reduction from 80.5 to 66.7 mg/dL 6

Antiplatelet Therapy:

• Aspirin 81-325 mg daily (CREST-2 used 325 mg) 6
• Consider clopidogrel 75 mg as alternative 4

Risk Factor Modification:

• Smoking cessation (mandatory)
• Diabetes control (HbA1c <7%)
• Weight management and physical activity 6

Step 3: Assess for High-Risk Features Warranting Revascularization Discussion

Most patients should NOT undergo revascularization. The 2024 ESC guidelines explicitly state: "In asymptomatic patients with ICA stenosis, in the absence of high-risk features and with a life expectancy <5 years, routine revascularization is not recommended" (Class III) 4.

Consider revascularization discussion ONLY if:

• Life expectancy >5 years 5, 4
• Documented progression of stenosis on serial imaging
• Silent cerebral infarcts on brain imaging ipsilateral to stenosis 7
• Impaired cerebrovascular reserve
• Contralateral carotid occlusion 5
• Planned cardiac surgery with symptomatic carotid stenosis >80% 7

Step 4: If Revascularization Considered, Apply Strict Selection Criteria

Critical Caveats About CREST-2 Revascularization Results:

The CAS benefit in CREST-2 must be interpreted with extreme caution 8:

• Periprocedural complication rates were exceptionally low (1.3-1.5%)—far below real-world rates
• Highly selected, low-risk patients (many high-risk features excluded)
• Expert operators at high-volume centers
• The benefit was "fragile" and may not generalize 8

If proceeding with revascularization:

CAS may be considered over CEA if:

• Age <70 years 5
• Unfavorable neck anatomy (high bifurcation, prior neck surgery/radiation, contralateral vocal cord paralysis) 9, 10
• Performed at center with documented <3% periprocedural stroke/death rate 5

CEA traditionally preferred over CAS if:

• Age >70 years 5
• Favorable surgical anatomy
• However, CREST-2 showed CEA provided no significant benefit over IMM alone 1

Absolute contraindications to revascularization:

• <50% stenosis 9, 10
• Chronic total occlusion 9, 10
• Life expectancy <5 years 4
• Severe disability (Modified Rankin Scale ≥3) 10

Common Pitfalls to Avoid

1. Assuming historical trial results apply today: ACAS and ACST were conducted before modern statin therapy, intensive BP control, and contemporary antiplatelet regimens. Their results showing CEA benefit are outdated 2, 11.

2. Overestimating revascularization benefit: The absolute risk reduction in CREST-2 was small (1.95% for CEA, 2.85% for CAS over 4 years) 1. Number needed to treat with CAS was 35 to prevent one event 1.

3. Underestimating IMM effectiveness: When properly implemented, IMM achieved 61% of patients at BP target and 67% at LDL target, with stroke rates comparable to or better than revascularization 6.

4. Ignoring periprocedural risk: Real-world complication rates typically exceed the 1.3-1.5% seen in CREST-2. Any center considering revascularization must document <3% periprocedural stroke/death rate 5, 4.

5. Failing to achieve IMM targets before considering intervention: Many CREST-2 patients missed medical therapy targets in all groups 8. Optimization of medical therapy must be exhausted first.

Reconciling Divergent Evidence

Why did CAS show benefit but CEA did not?

The aggregated control group analysis suggests this may reflect control arm variability rather than true differential efficacy 1. When both interventions were compared to a single merged control group, CAS showed 50.4% relative risk reduction (p=0.0089) while CEA remained non-significant (p=0.0871) 1. However, the absolute event rates were low across all groups, and longer follow-up may eventually show CEA benefit 12.

Guideline Consistency:

Current guidelines written before CREST-2 (2011 AHA/ASA, 2018 Canadian) suggested CEA "may be considered" for selected asymptomatic patients with 60-99% stenosis 5, 9, 10. The 2024 ESC guidelines, incorporating more recent evidence, explicitly recommend against routine revascularization in asymptomatic patients without high-risk features 4. The 2021 AHA/ASA stroke prevention guideline does not specifically address asymptomatic stenosis in detail 13.

Bottom Line for Clinical Practice

Intensive medical management is sufficient for the overwhelming majority of patients with asymptomatic carotid stenosis. Revascularization should be reserved for the rare patient who meets ALL of the following:

• Truly asymptomatic with ≥70% stenosis
• Life expectancy >5 years
• High-risk features present (silent infarcts, progression, contralateral occlusion)
• Optimal medical therapy achieved and maintained
• Access to operator/center with documented <3% complication rate
• Patient fully informed and preferring intervention after shared decision-making

The CREST-2 results validate a conservative, medically-focused approach and should substantially reduce the number of patients undergoing prophylactic carotid revascularization 11.